<?xml version='1.0' encoding='utf-8'?>
<document id="21788355"><sentence text="Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor."><entity charOffset="16-25" id="DDI-PubMed.21788355.s1.e0" text="topotecan" /><entity charOffset="31-40" id="DDI-PubMed.21788355.s1.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.21788355.s1.e0" e2="DDI-PubMed.21788355.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21788355.s1.e0" e2="DDI-PubMed.21788355.s1.e1" /></sentence><sentence text="Low dose metronomic (LDM) chemotherapy, combined with VEGF signaling pathway inhibitors, is a highly effective strategy to coordinately inhibit angiogenesis and tumor growth in many adult preclinical cancer models" /><sentence text=" We have tested the efficacies of daily oral LDM topotecan alone and in combination with pazopanib, a VEGF receptor inhibitor, in three pediatric extracranial solid tumor mouse models"><entity charOffset="49-58" id="DDI-PubMed.21788355.s3.e0" text="topotecan" /><entity charOffset="89-98" id="DDI-PubMed.21788355.s3.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.21788355.s3.e0" e2="DDI-PubMed.21788355.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21788355.s3.e0" e2="DDI-PubMed.21788355.s3.e1" /></sentence><sentence text="" /><sentence text="In vitro dose-response study of topotecan and pazopanib was conducted on several neuroblastoma, osteosarcoma, and rhabdomyosarcoma cell lines"><entity charOffset="32-41" id="DDI-PubMed.21788355.s5.e0" text="topotecan" /><entity charOffset="46-55" id="DDI-PubMed.21788355.s5.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.21788355.s5.e0" e2="DDI-PubMed.21788355.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21788355.s5.e0" e2="DDI-PubMed.21788355.s5.e1" /></sentence><sentence text=" In vivo antitumor efficacies of the LDM topotecan and pazopanib as single agents and in combination were tested on 4 subcutaneous xenograft models and on 2 neuroblastoma metastatic models"><entity charOffset="41-50" id="DDI-PubMed.21788355.s6.e0" text="topotecan" /><entity charOffset="55-64" id="DDI-PubMed.21788355.s6.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.21788355.s6.e0" e2="DDI-PubMed.21788355.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21788355.s6.e0" e2="DDI-PubMed.21788355.s6.e1" /></sentence><sentence text=" Circulating angiogenic factors such as circulating endothelial cells (CEC), circulating endothelial pro genitor cells (CEP), and microvessel densities were used as surrogate biomarker markers of antiangiogenic activity" /><sentence text="" /><sentence text="In vitro, topotecan caused a dose-dependent decrease in viabilities of all cell lines, while pazopanib did not"><entity charOffset="10-19" id="DDI-PubMed.21788355.s9.e0" text="topotecan" /><entity charOffset="93-102" id="DDI-PubMed.21788355.s9.e1" text="pazopanib" /><pair ddi="false" e1="DDI-PubMed.21788355.s9.e0" e2="DDI-PubMed.21788355.s9.e0" /><pair ddi="false" e1="DDI-PubMed.21788355.s9.e0" e2="DDI-PubMed.21788355.s9.e1" /></sentence><sentence text=" In vivo, combination of topotecan + pazopanib (TP + PZ) showed significant antitumor activity and significant enhancement in survival compared with the respective single agents in all models"><entity charOffset="25-46" id="DDI-PubMed.21788355.s10.e0" text="topotecan + pazopanib" /><entity charOffset="48-55" id="DDI-PubMed.21788355.s10.e1" text="TP + PZ" /><pair ddi="false" e1="DDI-PubMed.21788355.s10.e0" e2="DDI-PubMed.21788355.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21788355.s10.e0" e2="DDI-PubMed.21788355.s10.e1" /></sentence><sentence text=" Reductions in viable CEP and/or CEC levels and tumor microvessel density were correlated with tumor response and therefore confirmed the antiangiogenic activity of the regimens" /><sentence text=" Pharmacokinetic studies of both drugs did not reveal any drug-drug interaction" /><sentence text="" /><sentence text="Metronomic administration of TP + PZ showed a statistically significant antitumor activity compared with respective single agents in pediatric tumor mouse models and represent a valid option as a maintenance therapy in aggressive pediatric solid tumors"><entity charOffset="29-36" id="DDI-PubMed.21788355.s14.e0" text="TP + PZ" /></sentence><sentence text="" /></document>